Varian

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

HistoSonics is a medical device company that develops non-invasive platforms utilizing histotripsy, a novel focused ultrasound therapy. The company's primary product is the Edison Histotripsy System, which received FDA De Novo clearance in October 2023 for the non-invasive destruction of liver tumors. Histotripsy uses focused sound energy to produce controlled acoustic cavitation that mechanically destroys and liquefies targeted tissue at sub-cellular levels without damaging surrounding healthy tissue. The Edison System combines proprietary technology with advanced imaging to deliver personalized, non-invasive treatments with precision and control. It allows physicians to monitor tissue destruction in real-time, offering visualization and control not available with existing modalities. The system achieved a 95.5% technical success rate in clinical trials for precisely targeting and destroying liver tumors. HistoSonics is currently focused on commercializing the Edison System for liver treatments in the US and select global markets while exploring expanded applications for histotripsy in other organs such as the kidney, pancreas, and prostate.
Key customers and partnerships
HistoSonics has partnered with leading institutions across the US and internationally to develop multi-disciplinary histotripsy liver programs. The company conducted clinical trials at 13 sites across the US and Europe, including Mutua Terrassa Hospital and Vall D'Hebron Hospital in Barcelona, Spain. HistoSonics also maintains research collaborations with the University of Michigan, where histotripsy was originally developed, and the University of Wisconsin, which provides critical product development capabilities and validation of the company's non-invasive approach across multiple applications. In August 2024, HistoSonics announced plans to initiate the BOOMBOX Master Study to further evaluate the Edison System for liver tumor treatment across multidisciplinary users.

ZAP Surgical Systems designs and manufactures the ZAP-X Gyroscopic Radiosurgery platform, an advanced cranial radiosurgery system. The ZAP-X system utilizes a gyroscopic motion to direct radiation beams from hundreds of angles with sub-millimeter precision, allowing focused targeting of tumors while minimizing exposure to healthy brain tissue. It is the first and only dedicated radiosurgery platform to eliminate the need for radioactive Cobalt-60 sources, instead utilizing a modern linear accelerator to produce radiation.A key feature of the ZAP-X system is its vault-free design, which typically eliminates the need for costly shielded treatment rooms. This reduces the complexities and costs associated with traditional radiosurgery systems.The ZAP-X platform received FDA clearance in September 2017, Japanese Shonin clearance in April 2020, and CE Mark clearance in February 2021.&nbsp;Key customers and partnershipsZAP Surgical Systems serves a diverse range of customers in the healthcare sector, including medical centers and hospitals. As of April 2023, the 1,000th patient had been treated with the ZAP-X platform. In March 2021, the first ZAP-X system was commissioned at the Miami Neuroscience Center at Larkin Community Hospital in Florida. In April 2022, Baptist Health South Florida used the ZAP-X platform for advanced brain tumor treatments at the Miami Neuroscience Institute and Miami Cancer Institute.In October 2022, the University Hospital in Olsztyn, in collaboration with the University of Warmia and Mazury, became the first center in Poland and Eastern Europe to offer ZAP-X treatments. The European Radiosurgery Center Munich, a radiosurgery provider, initiated ZAP-X patient treatments in 2021 and has since treated over 300 patients (April 2023).

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

<div>
 
 COTA Healthcare is a bioinformatics startup that provides real-world data and analytics solutions focused on cancer care. COTA&rsquo;s platform uses data from a wide range of data sources, including electronic health records, clinical trials, and patient registries. Through its proprietary technology and analytics, COTA organizes and analyzes this data to offer insights into patient outcomes, treatment effectiveness, and the cost-effectiveness of various treatments. These insights have the potential to enhance patient care, expedite drug development, and guide policy decisions.
 
 
 
 
 The firm offers six different services to cater to the diverse needs of its target audience. These offerings encompass real-world data analytics, data abstraction and curation, as well as data consulting and advisory services. Operating as a B2B entity, COTA collaborates with pharmaceutical companies, academic institutions, healthcare providers, and health plans. As of May 2023, the company had over 2 million individuals diagnosed with cancer and more than 1,500 providers in its network.&nbsp;
 
 
 Key customers and partnerships
 
 
 In March 2021, the company partnered with Kite, a Gilead company, through which COTA&rsquo;s real-world data would be used to accelerate Kite&rsquo;s drug development pipeline. The company partnered with molecular testing company Genomic Testing Cooperative (GTC) in March 2023&nbsp; to combine COTA&rsquo;s clinical oncology real-world data with GTC&rsquo;s genomics testing data to support precision medicine-based care delivery. The company has also partnered with leading cancer organizations, including the American Cancer Society, the National Cancer Institute, and the Dana-Farber Cancer Institute.
 
 
 Funding and financials
 
 
 The company&rsquo;s most recent funding round was in October 2022, where it raised an unspecified amount in a Series E funding round led by Deerfield Management. The funds were used to accelerate and further diversify COTA's oncology real-world data products and services. 
 
 
 
</div>

Lucata leverages patented migrating thread technology to massively scale unified memory and conduct high performance, multi-hop analytics, including exhaustive breadth-first search (BFS), on unpruned and unsharded  databases with 1 trillion vertices and beyond. Organizations can now use their existing graph database software or custom graph solutions to analyze deeper connections on much larger graphs than ever before possible. Lucata solutions support groundbreaking graph analytics and improved machine learning and AI for organizations in financial services, cybersecurity, blockchain, healthcare, pharmaceuticals, telecommunications, ecommerce, government and more. The company has offices in Palo Alto, New York City, and South Bend, Ind. For more information, visit www.Lucata.com. Key technical claims: 1.	Data doesn’t move, processing context moves to the data in a global unified address space. 2.	Latency of both network and memory access are hidden due to the migrating threads and multithreaded Lucata cores. 3.	Energy efficient high density memory architecture. 4.	Drastic reduction in OS intervention. 5.	Architecture doesn't rely on data locality for optimal performance. 6.	Linear performance growth with hardware scale up to 64,000 nodes. 7.	Single shared address space up to 18 Exabytes.

Bendit is a medical company that develops and manufactures innovative catheters based on a unique bending technology, enabling extensive steering abilities in micro diameter and conventional catheter wires and tubes. The company is a joint venture between three experienced groups from production, quality & regulation, and development in the medical field.

COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real world data. By using proprietary technology, advanced analytics and deep expertise to organize complex data, COTA provides a comprehensive picture of cancer that can be used to advance care and research.

HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Arterys is the market leader and the world's first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions.

ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® radiosurgery platform. ZAP-X incorporates a unique self-shielded design that typically eliminates the need for traditional radiation vaults, and thus enables simple point-of-care delivery in locations previously unfeasible or cost-prohibitive, including physician offices, ambulatory surgery centers, and satellite facilities.

Oncora Medical is a digital health company integrating big data and machine learning into radiation oncology. Founded in 2014, Oncora's intuitive software platform allows for better collection and application of real world data for all healthcare related decisions, for the benefit of the patient.

ABK Biomedical combines the clinical market with biomaterials. It specializes in improving treatment options for patients with hypervascular tumors.  The company is dedicated to transforming an interventional radiology procedure called embolization.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production center. Fusion’s deep radiochemistry expertise presents a technology platform that can be replicated to turn internalizing antibodies that have previously demonstrated limited clinical efficacy into highly effective cytotoxic drugs. Fusion’s ability to link effective isotopes to the targeting antibody allows for the creation of optimized agents for both diagnostic imaging and radioimmunotherapy (Precision Medicine). Following positive tumor identification with the imaging agent, treatment with the antibody linked to a therapeutic isotope delivers a cytotoxic payload into the cancer cell. Fusion’s lead product candidate, FPX-01, is a precision RIT that is a product of this innovative approach. FPX-01 has been designed to internalize targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody causes selective and extremely effective cytotoxicity of tumor cells at relatively low doses of radioactivity.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Varian Medical Systems, headquartered globally in Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection.

Varian’s RapidArc Dynamic Solution Unlocks New Dimensions in Treatment Planning and Delivery

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

Software that provides a list of possible diseases based on data collected from patients. Platforms are only used for initial assessments.

Platforms and software that generates alerts based on patient treatment and current status.

Platforms and software that monitor and track treatment plans of patients, identifies possible treatment issues, and suggests alternative treatment options.

Workflow management software that helps clinicians track and follow procedure for operations.

Companies that use GenAI as a core part of their product offering for Clinical Decision Support Systems

Varian

Featured Industries

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless